These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32376237)

  • 1. Clinical Updates Regarding Multiple Myeloma From the 2019 American Society of Hematology Annual Meeting.
    Terpos E; Ntanasis-Stathopoulos I;
    Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):499-508. PubMed ID: 32376237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018.
    Terpos E; Ntanasis-Stathopoulos I;
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e324-e336. PubMed ID: 31076371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
    Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
    Front Oncol; 2020; 10():624661. PubMed ID: 33680948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016.
    Terpos E;
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):329-339. PubMed ID: 28462890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
    Mateos MV; Cavo M; Blade J; Dimopoulos MA; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Krevvata M; Chen Y; Wang J; Kudva A; Ukropec J; Wroblewski S; Qi M; Kobos R; San-Miguel J
    Lancet; 2020 Jan; 395(10218):132-141. PubMed ID: 31836199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
    Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
    Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017.
    Terpos E;
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):321-334. PubMed ID: 29576386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
    Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Kaplan P; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Chiu C; Wang J; Carson R; Crist W; Deraedt W; Nguyen H; Qi M; San-Miguel J;
    N Engl J Med; 2018 Feb; 378(6):518-528. PubMed ID: 29231133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016.
    Tandon N; Kumar SK
    Indian J Hematol Blood Transfus; 2017 Jun; 33(2):153-158. PubMed ID: 28596644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
    Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
    J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020.
    Du J; Zhuang J
    Chronic Dis Transl Med; 2021 Dec; 7(4):220-226. PubMed ID: 34786541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
    Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
    Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.
    Michaleas S; Penninga E; Hovgaard D; Dalseg AM; Rosso A; Sarac SB; Jimenez JC; Fernández LL; Fernández CP; Mangas-SanJuan V; Garcia I; Payares-Herrera C; Sancho-López A; Enzmann H; de Castro Lopes Silva MSS; Duarte S; Pignatti F
    Oncologist; 2020 Dec; 25(12):1067-1074. PubMed ID: 33026700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
    Moreau P; Attal M; Hulin C; Arnulf B; Belhadj K; Benboubker L; Béné MC; Broijl A; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Garderet L; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Lenain P; Macro M; Mathiot C; Orsini-Piocelle F; Perrot A; Stoppa AM; van de Donk NW; Wuilleme S; Zweegman S; Kolb B; Touzeau C; Roussel M; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Fermand JP; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Zhuang S; Chiu C; Pei L; de Boer C; Smith E; Deraedt W; Kampfenkel T; Schecter J; Vermeulen J; Avet-Loiseau H; Sonneveld P
    Lancet; 2019 Jul; 394(10192):29-38. PubMed ID: 31171419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy.
    Park SS; Min Byun J; Yoon SS; Kim K; Jung SH; Lee JJ; Min CK
    Br J Haematol; 2021 Apr; 193(1):101-112. PubMed ID: 33368165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis.
    Cao Y; Wan N; Liang Z; Xie J; Wang S; Lin T; Zhang T; Jiang J
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e478-e488. PubMed ID: 31130487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
    Bhatnagar V; Gormley NJ; Luo L; Shen YL; Sridhara R; Subramaniam S; Shen G; Ma L; Shord S; Goldberg KB; Farrell AT; McKee AE; Pazdur R
    Oncologist; 2017 Nov; 22(11):1347-1353. PubMed ID: 28904172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
    Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
    Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.